The C.A.M. Report
Complementary and Alternative Medicine: Fair, Balanced, and to the Point
  • About this web log

    This blog is intended as an objective and dispassionate source of information on the latest CAM research. Since my background is in pharmacy and allopathic medicine, I view all CAM as advancing through the development pipeline to eventually become integrated into mainstream medical practice. Some will succeed while others fail. But all are treated fairly here.

  • About the author

    John Russo, Jr., PharmD, is president of The MedCom Resource, Inc. Previously, he was senior vice president of medical communications at www.Vicus.com, a complementary and alternative medicine website.

  • Common sense considerations

    The material on this weblog is for informational purposes. It is not medical advice or counsel. Be smart, consult your health professional before using CAM.

  • Support this site

    If you found the information here helpful, please consider supporting this site.If you found the information here helpful, please consider supporting this site.

  • Recent Posts

  • Recent Comments

    Use of CAM by people with cancer

    Researchers at the University of Birmingham, in the UK, investigated the prevalence of herbal medicine use among cancer patients in the West Midlands — a metropolitan county in western central England.

    First, the details.

    • 1498 oncology patients being followed at a hospital in Coventry were surveyed.
    • They were asked about herbal medicine use since their cancer diagnosis.
    • Associations between sociodemographic, cancer-related characteristics, and herbal medicine use were evaluated.

    And, the results.

    • The prevalence of herbal medicine use was 20%.
    • Users were more likely to be affluent, female, and younger than 50 years.
    • Usage increased over time since cancer diagnosis.

    The bottom line?

    The authors conducted another survey of 541 oncology patients in Birmingham with differing socioeconomic characteristics. The results showed no significant difference in estimated prevalence (17%).

    This study can be added to an earlier review of studies summarized here. In Europe and the UK, the prevalence of CAM in head and neck cancer patients is 23%.

    3/16/11 21:28 JR

    Leave a Comment

    You must be logged in to post a comment.